TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04201665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Patients will receive a single dose of carbetocin 100 mcg (Pabal ®) at admission to high dependency obstetric unit after cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.
Study: NCT03933813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron Sucrose
Description: Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
Study: NCT00389844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trainer component of the Exercise Plus Program
Description: With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trainer component of the Exercise Plus Program
Description: With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Trainer component of the Exercise Plus Program
Description: With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plus component (motivation) of the Exercise Plus Program
Description: Motivation only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plus component (motivation) of the Exercise Plus Program
Description: Motivation only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Plus Program (exercise + motivation)
Description: Exercise plus motivation
Study: NCT03279029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy of aortic valve

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsy of aortic valve
Study: NCT02428192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01274481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
Study: NCT00527735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
Study: NCT02968316

Intervention type: OTHER
Intervention: BIA measurement
Description: observation only
Study: NCT00527735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
Study: NCT01831167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic light
Study: NCT00723307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: White film-coated tablets, 850mg tablet twice daily, 1.5 years duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White coated tablet; one tablet twice daily; 1.5 years duration
Study: NCT00276510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761® (Tanakan®)
Description: 120 mg, 1 tablet twice a day, oral route, during 5 years.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet twice a day, oral route, during 5 years.
Study: NCT02210000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camicinal
Description: Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
Study: NCT05343858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Group 1: Spirulina platensis
Description: 16 g/day (two doses of 8g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2: Chlorella vulgaris
Description: 16 g/day (two doses of 8g)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Group 3: Control
Description: 16 g/day (two doses of 8g)
Study: NCT00205335

Intervention type: DEVICE
Group type: OTHER
Intervention: Ascencia Breeze Glucose meter
Description: All study participants received glucose meter and test strips.

Intervention type: DEVICE
Group type: OTHER
Intervention: Breeze Glucose Monitor (Bayer)
Description: Each participant received a Breeze monitor and glucose test strips.
Study: NCT04369378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation app usage
Description: Investigators will confirm eligibility of applicants, enroll participants in the study and provide an identification number for de-identification of the data, and provide a list of mental health resources to participants. Participants will then be sent a link to a Google Form for the pre-intervention survey, to be completed prior to first use of the mindfulness app. Participants will also be given access to the mindfulness app (Insight Timer), and instructed to use it for 10 min daily for 30 days. Two days before the end of the 30 day intervention period, participants will be sent a link to a Google Form for the post-intervention survey and will be asked to complete the survey within the next 3 days. Two months after the conclusion of the 30 day intervention period, participants will be sent a link to a Google Form for another post-intervention survey, and asked to complete it within 5 days.
Study: NCT00194805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth for Diabetes Self Management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth for Diabetes Self Management
Description: Web based education format delivered for a six month period
Study: NCT02152826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate
Description: Professional application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Description: Professional application
Study: NCT02723812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCFLU® Influenza vaccine (Split virion, Inactivated)
Study: NCT03633344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbowhite

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbowhite placebo
Study: NCT03795116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-RL phototherapy
Description: The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock irradiation
Description: The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
Study: NCT02447016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil/emtricitabine/rilpivirine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil/emtricitabine/efavirenz
Study: NCT01794988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Interactive Voice Response
Description: Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
Study: NCT00817713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel, Ivermectin, Albendazole
Description: Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months.
Study: NCT03437681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insufficient sleep
Description: Four days of insufficient sleep
Study: NCT02201615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal massage in childbirth
Study: NCT02706613

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Face to Face Pulmonary Rehabilitaton
Description: 6 week face to face, incremental exercise and education programme for people with COPD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Pulmonary Rehab
Description: 6 week online, incremental exercise and education programme for people with COPD
Study: NCT06236659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise
Description: Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise
Description: Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)
Study: NCT02751411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-enema with Promelaxin
Description: The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 4000
Description: Stool softener
Study: NCT03056027

Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocolordoppler ultrasound testicular evaluation
Description: Ecocolordoppler ultrasound testicular evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: Ecocolordoppler ultrasound testicular evaluation
Description: Ecocolordoppler ultrasound testicular evaluation
Study: NCT00923260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omentectomy
Description: After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
Study: NCT00477360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humeral surface replacement hemiarthroplasty (CAP)
Description: C.A.P hemiarthroplasty
Study: NCT03470246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for CABG patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for AVR patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACO intervention for MVR patients
Description: The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
Study: NCT02116673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive rest
Description: The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
Study: NCT02766192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIMBER Psychotherapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TIMBER Psychotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Study: NCT03644953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
Study: NCT01794988

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NO TIVR
Description: Control - no intervention
Study: NCT00681629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: 400-800 mg, oral, bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: 400-800 mg, oral, bid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Care Program (ICP)
Description: Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
Study: NCT00956917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Akern USA EFG
Description: Impedance measurement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RJL Impedance analyzer
Description: Impedance analyzer
Study: NCT05162183

Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the exposure group.